CD274 and Miyoshi myopathy: Ongoing phase I–II trials have been designed in RR-MM patients with the combination of DARA and the anti-PD-1 mAbs, pembrolizumab [99], nivolumab (NCT03184194, NCT01592370) or the anti-PD-L1, durvalumab (FUSION-MM-005) and atezolizumab (NCT02431208).